Speaking from the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, Michael Atkins, MD, of Georgetown University, Washington, DC, discusses the promising results from the Phase II KEYNOTE-427 study with pembrolizumab (NCT02853344), and the Phase III KEYNOTE-426 trial (NCT02853331) looking at the combination of pembrolizumab with axitinib for treating advanced renal cell carcinoma (RCC).
